Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $102.00 at Citizens Jmp

Protagonist Therapeutics (NASDAQ:PTGX) had its target price increased by Citizens Jmp from $69.00 to $102.00 in a report issued on Friday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other research analysts also recently commented on the company. Leerink Partnrs upgraded Protagonist Therapeutics to a “strong-buy” rating in a research note on Friday, September 12th. BTIG Research reaffirmed a “buy” rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, October 28th. Leerink Partners assumed coverage on shares of Protagonist Therapeutics in a report on Friday, September 12th. They issued an “outperform” rating and a $73.00 price objective on the stock. Citigroup raised their target price on shares of Protagonist Therapeutics from $72.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, JMP Securities upped their price target on shares of Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $82.08.

Protagonist Therapeutics Stock Down 0.3%

Shares of PTGX stock traded down $0.24 on Friday, reaching $79.54. The stock had a trading volume of 882,282 shares, compared to its average volume of 1,586,433. Protagonist Therapeutics has a 12 month low of $33.31 and a 12 month high of $93.25. The firm has a market capitalization of $4.95 billion, a price-to-earnings ratio of 128.29 and a beta of 2.22. The firm’s 50-day moving average is $68.54 and its two-hundred day moving average is $57.48.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.78% and a net margin of 21.94%. On average, sell-side analysts forecast that Protagonist Therapeutics will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In related news, Director William D. Waddill sold 12,000 shares of the firm’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $81.62, for a total transaction of $979,440.00. Following the transaction, the director directly owned 5,130 shares of the company’s stock, valued at approximately $418,710.60. This trade represents a 70.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 20,000 shares of company stock valued at $1,473,440 in the last 90 days. Corporate insiders own 4.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PTGX. Smartleaf Asset Management LLC increased its holdings in shares of Protagonist Therapeutics by 11.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after purchasing an additional 146 shares during the period. Guggenheim Capital LLC grew its position in Protagonist Therapeutics by 1.6% during the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock worth $1,062,000 after buying an additional 303 shares in the last quarter. Bessemer Group Inc. grew its position in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after buying an additional 318 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Protagonist Therapeutics by 13.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,738 shares of the company’s stock worth $182,000 after acquiring an additional 324 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in Protagonist Therapeutics by 4.1% in the 1st quarter. Hsbc Holdings PLC now owns 8,458 shares of the company’s stock valued at $405,000 after acquiring an additional 330 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.